Your session is about to expire
← Back to Search
Pneumovax 23- pneumococcal polysaccharide for Type 1 Diabetes
Study Summary
This trial looks at whether kids with type 1 diabetes have a strong enough immune response to the PPSV23 vaccination, and what might affect that response.
- Type 1 Diabetes
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Does eligibility for this clinical trial include individuals of all ages, or is there an upper age limit?
"This study only seeks participants that fall between the ages of 3 and 18. Out of all available clinical trials, 226 are dedicated to those under eighteen while 934 are tailored towards seniors over 65 years old."
To what degree is Pneumovax 23- pneumococcal polysaccharide safe for human consumption?
"Pneumovax 23- pneumococcal polysaccharide has been officially approved, so it is accorded a score of 3 in terms of safety."
How many individuals are partaking in this research program?
"Affirmative. Information hosted on the clinicaltrials.gov website indicates that this trial is actively enrolling participants, with an initial posting date of 4/30/2021 and most recent update occurring 11/9/2022. The research team requires 100 volunteers across a single site to complete the study."
Do I meet the prerequisites to take part in this clinical evaluation?
"To qualify for the trial, participants must suffer from type 1 diabetes mellitus and be 3 to 18 years old. The study aims to recruit a total of 100 individuals."
Is this medical research currently enrolling participants?
"According to clinicaltrials.gov, this trial is still searching for participants. The initial post was made on April 30th 2021 and the most recent revision occurred on November 9th 2022."
Share this study with friends
Copy Link
Messenger